| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
551.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 18.6 |
| Insider 6 Months : 18.6 |
| Insider 3/6 Months : 37.7 |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
| Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
1,254 |
20,641 |
171,008 |
| Total Sell Value |
$0 |
$10,922 |
$205,329 |
$1,825,540 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
10 |
20 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2020-02-20 |
4 |
D |
$25.90 |
$761,512 |
D/D |
(29,402) |
264,932 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2020-02-20 |
4 |
D |
$25.90 |
$186,817 |
D/D |
(7,213) |
203,040 |
|
- |
|
| Brady Ann |
President, TBIL |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
111,111 |
|
- |
|
| Hindman Andrew A. |
SVP, Chief Financial Officer |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
63,550 |
113,550 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
350,276 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
383,855 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
294,334 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
338,000 |
1,412,455 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
437,312 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
210,253 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
378,834 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2019-12-12 |
4 |
S |
$21.03 |
$21,598 |
D/D |
(1,027) |
145,253 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$62,779 |
D/D |
(3,567) |
175,334 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$43,067 |
D/D |
(2,447) |
318,312 |
|
- |
|
| Brady Ann |
President, TBIL |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$18,885 |
D/D |
(1,073) |
71,111 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$39,987 |
D/D |
(2,272) |
264,855 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$25,925 |
D/D |
(1,473) |
146,280 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2019-11-20 |
4 |
D |
$17.60 |
$152,733 |
D/D |
(8,678) |
1,074,455 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$47,379 |
D/D |
(2,692) |
231,276 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2019-11-20 |
4 |
D |
$17.60 |
$39,987 |
D/D |
(2,272) |
259,834 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2019-08-20 |
4 |
D |
$21.51 |
$58,292 |
D/D |
(2,710) |
233,968 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2019-08-20 |
4 |
D |
$21.51 |
$31,663 |
D/D |
(1,472) |
147,753 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2019-08-20 |
4 |
D |
$21.51 |
$50,226 |
D/D |
(2,335) |
320,759 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2019-08-20 |
4 |
D |
$21.51 |
$48,871 |
D/D |
(2,272) |
267,127 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2019-08-20 |
4 |
D |
$21.51 |
$186,664 |
D/D |
(8,678) |
1,083,133 |
|
- |
|
543 Records found
|
|
Page 10 of 22 |
|
|
0.13 (1.53%) 
